Education only. These tools do not diagnose cancer, assign your stage or recommend an individual treatment. No names, reports or identifying information are requested. Selections stay in this page and are not saved. Evidence check: 30 October 2026.
1. Symptom Awareness Guide
2. Understanding My Pathology Report
Select a term to understand it. Do not paste a personal report.
3. FIGO 2023 Staging Explorer
Explore an already named category. This does not calculate a stage from symptoms or test results. Formal staging requires integrated pathology and specialist review.
4. Molecular Classification Explorer
5. Treatment Pathway Explorer
6. Questions to Ask the Oncologist
Choose discussion topics. The checklist contains no personal identifiers.
References and review status
- Berek et al. FIGO staging of endometrial cancer, 2023
- ESGO–ESTRO–ESP endometrial carcinoma guideline update, 2025
- ACOG updated postmenopausal bleeding guidance, April 2026
- FDA pembrolizumab–chemotherapy approval / KEYNOTE-868, June 2024
- EMA: Imfinzi, current European indications
Evidence/editorial check: 30 October 2026. Individual physician review is not recorded. Local approvals, resources and clinical guidance must be confirmed by the treating team.
Evidence scope and update policy